rr 生物标志物分析原则（NSCL-H）.
vv 晚期或转移性疾病的生物标志物指导治疗原则（NSCL-J）
vvv For patients who require an urgent start to therapy but biomarker testing is pending, consider holding immunotherapy for one cycle, unless confirmed that no driver mutations are present.
www If patient has not received platinum-doublet chemotherapy, refer to "systemic therapy." If patient received platinum chemotherapy and anti-PD-1/PD-L1, refer to “subsequent therapy.” NCCN-NSCLC-2026V6 NCCN非小细胞肺癌指南导航
